|
|
Post by twibs66 on Aug 17, 2016 7:55:51 GMT -5
|
|
|
|
Post by nadathing on Aug 17, 2016 8:14:08 GMT -5
My mother in law just had to replace her two pens that were unused, but old. She paid $200 two years ago and paid $320 for two new pens in June. She asked if she could buy just one and was told no. What I find hard to believe is that we cannot find anyone to partner with on this endeavor.
|
|
|
|
Post by kbrion77 on Aug 17, 2016 8:40:14 GMT -5
This is where my naiveness kicks in. I have no idea what it takes to run a company and maybe this secrecy pays off so this is basically a mini rant. How does MNKD management (I would probably point to Ray) not give an exclusive interview to somebody/anybody on what they are trying to accomplish with Afrezza and Inhaled Epi. Two massive markets in which the cost of medication has astronomically risen and caused serious burdens for patients. I mean just an interview/article with the theme of little old Mannkind trying to take on 2 massive markets with their Techno platform to benefit patients. I would think a company on the brink of collapse would want all the positive attention they could get right now. What do I know though.
|
|
|
|
Post by rravis1914 on Aug 17, 2016 10:04:36 GMT -5
ALL of you young tech savvy people should tweet Mike C about this. Maybe it will set a fire in the proper place.
|
|
|
|
Post by mnholdem on Aug 17, 2016 10:05:58 GMT -5
Do you see the black bar at the bottom? Based on what was discussed at the 2Q16 earnings call, I believe that the company has made the "Go" decision. So they could, in fact, be negotiating with a pharmaceutical company or companies to evaluate which provides the best business opportunity. 
You're right about weighing the need for secrecy against the need to prop up the company's image, but Matt spoke about this subject of negotiations over a year ago. Management will not divulge that they are in specific talks or provide any kind of timeline for such negotiations until they are at the signing stage, because pre-announcing that you're in talks will give the other party leverage. |
|
|
|
Post by audiomr on Aug 17, 2016 12:14:30 GMT -5
This is where my naiveness kicks in. I have no idea what it takes to run a company and maybe this secrecy pays off so this is basically a mini rant. How does MNKD management (I would probably point to Ray) not give an exclusive interview to somebody/anybody on what they are trying to accomplish with Afrezza and Inhaled Epi. Two massive markets in which the cost of medication has astronomically risen and caused serious burdens for patients. I mean just an interview/article with the theme of little old Mannkind trying to take on 2 massive markets with their Techno platform to benefit patients. I would think a company on the brink of collapse would want all the positive attention they could get right now. What do I know though. You need somebody interested in doing and publishing the interview. Might be hard to come up with at this stage of where everything is. If Afrezza takes off and begins to displace other therapy options, that will be a big story. And the epi-Cricket will be a story when it gets close to release. |
|
|
|
Post by sportsrancho on Aug 18, 2016 14:02:02 GMT -5
|
|
|
|
Post by surplusvalue on Aug 18, 2016 14:47:54 GMT -5
The CEO of Mylan is politically well connected and this has been used to squash competition to its products in at least one case explicitly. You can be sure that these connections will be used to buffer Mylan from criticism of these price increases. |
|
|
|
Post by sportsrancho on Aug 18, 2016 16:54:57 GMT -5
|
|
|
|
Post by slugworth008 on Aug 18, 2016 19:51:57 GMT -5
Here's my feeble attempt at marketing "Tired of getting pricked by epipen pricing? Switch to Afrezza we'll give you an inhaler for free! It's a slow night here - LOL |
|
|
|
Post by sportsrancho on Aug 18, 2016 19:55:45 GMT -5
Here's my feeble attempt at marketing "Tired of getting pricked by epipen pricing? Switch to Afrezza we'll give you an inhaler for free! It's a slow night here - LOL Good one! That's because you're not drinking:-))) |
|
|
|
Post by peppy on Aug 18, 2016 20:18:55 GMT -5
Here's my feeble attempt at marketing "Tired of getting pricked by epipen pricing? Switch to Afrezza we'll give you an inhaler for free! It's a slow night here - LOL Good one! That's because you're not drinking:-)))
|
|
|
|
Post by vestful on Aug 18, 2016 20:33:10 GMT -5
Instead of paying for an expensive prick breathe easy with Afrezza
|
|
|
|
Post by kbrion77 on Aug 21, 2016 18:43:33 GMT -5
gizmodo.com/when-martin-shkreli-calls-a-pharma-company-out-you-kno-1785538433This topic continues to gain a lot of steam. The simplest form of media from MNKD to gain new attention to what they are trying to accomplish with an inhaled (and hopefully cheaper) version of EpiPen would in my opinion work wonders. A person could read the article that has a child with severe allergies but also have a family member struggling with diabetes and next thing you know that's another avenue of potential Afrezza awareness. I know I'll get the standard, "well that can't divulge what they are working on" but we are in the 11th hour. And honestly even if we weren't in the 11th hour this would be a great opportunity to raise awareness to the company. Rant over.....
|
|
|
|
Post by wmdhunt on Aug 22, 2016 16:26:02 GMT -5
Along the way, EpiPen’s wholesale price rose roughly 400 percent from about $57 each when Mylan acquired the product. Time for MNKD to DISRUPT this! I'm not diabetic nor need an epi but I am tired of getting pricked. Please get moving on epi too, now. Senators are examining Mylan’s price increases for the popular EpiPen allergy shot bloom.bg/2bcyfTz
|
|
